ValuEngine lowered shares of Benitec Biopharma Limited (NASDAQ:BNTC) from a hold rating to a sell rating in a research note issued to investors on Thursday.

Separately, Maxim Group restated a hold rating on shares of Benitec Biopharma Limited in a research note on Wednesday, May 31st.

Benitec Biopharma Limited (NASDAQ:BNTC) opened at 2.11 on Thursday. The company’s 50-day moving average is $2.10 and its 200-day moving average is $2.43. Benitec Biopharma Limited has a one year low of $1.30 and a one year high of $5.48. The firm’s market capitalization is $21.64 million.

ILLEGAL ACTIVITY NOTICE: “Benitec Biopharma Limited (BNTC) Rating Lowered to Sell at ValuEngine” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at

About Benitec Biopharma Limited

Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Benitec Biopharma Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma Limited and related stocks with our FREE daily email newsletter.